174 related articles for article (PubMed ID: 30642542)
1. Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
Wu L; Dell'Anno I; Lapidot M; Sekido Y; Chan ML; Kohno M; Serre-Beinier V; Felley-Bosco E; de Perrot M
Lung Cancer; 2019 Jan; 127():138-145. PubMed ID: 30642542
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
Chapel DB; Churg A; Santoni-Rugiu E; Tsujimura T; Hiroshima K; Husain AN
Lung Cancer; 2019 Jan; 127():69-75. PubMed ID: 30642555
[TBL] [Abstract][Full Text] [Related]
3. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
[TBL] [Abstract][Full Text] [Related]
4. Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma.
D'Amato-Brito C; Cipriano D; Colin DJ; Germain S; Seimbille Y; Robert JH; Triponez F; Serre-Beinier V
Oncotarget; 2016 Mar; 7(10):11512-25. PubMed ID: 26883190
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
8. Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
Armato SG; Labby ZE; Coolen J; Klabatsa A; Feigen M; Persigehl T; Gill RR
Lung Cancer; 2013 Nov; 82(2):190-6. PubMed ID: 24018024
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for immunotherapy in malignant pleural mesothelioma?
Tartarone A; Lerose R; Aieta M
Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
[TBL] [Abstract][Full Text] [Related]
11. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
Liu H; Wu L; Ji K; Wang W
Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
[TBL] [Abstract][Full Text] [Related]
13. CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
Komiya E; Ohnuma K; Yamazaki H; Hatano R; Iwata S; Okamoto T; Dang NH; Yamada T; Morimoto C
Biochem Biophys Res Commun; 2014 May; 447(4):609-15. PubMed ID: 24747072
[TBL] [Abstract][Full Text] [Related]
14. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
Thellung S; Favoni RE; Würth R; Nizzari M; Pattarozzi A; Daga A; Florio T; Barbieri F
Curr Drug Targets; 2016; 17(7):824-49. PubMed ID: 26240051
[TBL] [Abstract][Full Text] [Related]
16. A catalogue of treatment and technologies for malignant pleural mesothelioma.
Schunselaar LM; Quispel-Janssen JM; Neefjes JJ; Baas P
Expert Rev Anticancer Ther; 2016; 16(4):455-63. PubMed ID: 26943000
[TBL] [Abstract][Full Text] [Related]
17. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
Minnema-Luiting J; Vroman H; Aerts J; Cornelissen R
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29601534
[TBL] [Abstract][Full Text] [Related]
19. Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.
Facchetti G; Petrella F; Spaggiari L; Rimoldi I
Eur J Med Chem; 2017 Dec; 142():266-270. PubMed ID: 28800871
[TBL] [Abstract][Full Text] [Related]
20. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]